2023-02970. Notice of Closed Meeting  

  • Start Preamble

    Pursuant to 5 U.S.C. 1009(d), notice is hereby given of the following meeting.

    The meeting will be closed to the public in accordance with the provisions set forth in 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended, and the Determination of the Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, CDC, pursuant to Public Law 117-286. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: Disease, Disability, and Injury Prevention and Control Special Emphasis Panel (SEP)—RFA-PS23-001, Increasing PrEP Use Among Disproportionately Affected Populations in the United States and RFA-PS23-003, Exploring Preferences for Long-Acting Antiretroviral Therapies (LA-ART) in a Community-Based Sample of Priority Populations Living with HIV Who are Disproportionately Affected.

    Date: May 11-12, 2023.

    Time: 10 a.m.-5 p.m. (EDT).

    Place: Teleconference, Centers for Disease Control and Prevention, Room 1077, 8 Corporate Blvd., Atlanta, GA 30329.

    Agenda: To review and evaluate grant applications.

    For Further Information Contact: Gregory Anderson, M.S., M.P.H., Scientific Review Officer, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, CDC, 1600 Clifton Road NE, Mailstop US8-1, Atlanta, Georgia 30329, Telephone: (404) 718-8833, Email: GAnderson@cdc.gov.

    The Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention, has been delegated the authority to sign Federal Register notices pertaining to announcements of meetings and other committee management activities, for both the Centers for Disease Control and Start Printed Page 9289 Prevention and the Agency for Toxic Substances and Disease Registry.

    Start Signature

    Kalwant Smagh,

    Director, Strategic Business Initiatives Unit, Office of the Chief Operating Officer, Centers for Disease Control and Prevention.

    End Signature End Preamble

    [FR Doc. 2023-02970 Filed 2-10-23; 8:45 am]

    BILLING CODE 4163-18-P

Document Information

Published:
02/13/2023
Department:
Centers for Disease Control and Prevention
Entry Type:
Notice
Document Number:
2023-02970
Dates:
May 11-12, 2023.
Pages:
9288-9289 (2 pages)
PDF File:
2023-02970.pdf